不同剂量头孢噻肟钠用于肺癌根治术围术期预防术后感染疗效比较  

Comparative Efficacy of Different Doses of Cefotaxime Sodium for Preventing Postoperative Infection in Perioperative Period of Radical Resection of Lung Cancer

作　　者：钟宏城[1] 李晓剑[1] Zhong Hongcheng Li Xiaojian(Department of Cardiothoracic Surgery, The Fifth Hospital Affiliated to Zhongshan University, Zhuhai, Guangdong, China 519000)

机构地区：[1]中山大学附属第五医院胸心外科,广东珠海519000

出　　处：《中国药业》2017年第14期48-50,共3页China Pharmaceuticals

摘　　要：目的探讨肺癌根治术围术期使用不同剂量头孢噻肟钠预防术后感染的疗效和安全性。方法选取2015年2月至2016年8月医院收治的行肺癌根治术患者92例,随机分为大剂量组和小剂量组,各46例,围术期分别予3 g和1.5 g头孢噻肟钠预防术后感染。结果两组患者术后感染发生率均为6.52%(P>0.05);小剂量组用药不良反应发生率为2.17%,明显低于大剂量组的13.04%(P<0.05);两组患者治疗后白蛋白、血红蛋白、白细胞水平均明显优于治疗前(P<0.05),但组间比较无明显差异(P>0.05)。结论肺癌根治术围术期使用小剂量头孢噻肟钠可有效预防术后感染,改善机体营养,且安全性高,值得临床推广。Objective To investigate the efficacy and safety of different doses of cefotaxime in the prevention of postoperative infection in perioperative period of radical resection of lung cancer. Methods Totally 92 patients with radical resection of lung cancer from February 2015 to August 2016 were randomly divided into the high dose group and the low dose group,46 cases in each group. The high dose group was treated with 3 g doses of cefotaxime to prevent postoperative infection,while the low dose group was treated with 1. 5 g dose cefotaxime. Results Both of the incidence rates of postoperative infection in the two groups were 6. 52%（ P〈0. 05）. The incidence rate of adverse reactions in the low dose group was 2. 17%,which was significantly lower than 13. 04% in the high dose group（ P〈0. 05）. The levels of albumin,hemoglobin and WBC in the two groups were significantly better than those before treatment（ P〈0. 05）,but there was no significant difference between the two groups（ P〉0. 05）. Conclusion The use of small dose cefotaxime in perioperative period of radical resection of lung cancer can effectively prevent postoperative infection and improve the body nutrition,it is safe and worthy of clinical promotion.

关 键 词：肺癌根治术 围术期 剂量 头孢噻肟钠 术后感染 临床疗效 安全性 

分 类 号：R969.4[医药卫生—药理学] R619.3[医药卫生—药学]